Businessweek

Cell Therapeutics, Inc. Presents at UBS Global Healthcare Conference, May-21-2013 02:30 PM. Venue: Sheraton New York Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: James A. Bianco, Principal Founder, Chief Executive Officer, President and Executive Director.

Cell Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. Net loss was $19,384,000 or $0.18 per basic and diluted share against $17,446,000 or $0.43 per basic and diluted share for the same period last year. Loss from operations was $18,427,000 against $18,098,000 for the same period last year. Total revenues for the first quarter of 2013 were $1.1 million. The revenues were solely attributable to net product sales of PIXUVRI. CTI sells PIXUVRI directly to health care providers and through a limited number of wholesale distributors in the E.U. The company reaffirms prior financial guidance that, for 2013, loss from operations is expected to be approximately $60 to $65 million, excluding non-cash stock-based compensation expense. Actual financial results for 2013 will vary based upon many factors, including the growth of PIXUVRI sales and determination of reimbursement rates for PIXUVRI in the E.U., the rate of patient enrollment in pacritinib clinical trials that are ongoing and planned for initiation in 2013 and other factors.

Cell Therapeutics, Inc. announced that they will report Q1, 2013 results After-Market on May 02, 2013

Cell Therapeutics, Inc., Q1 2013 Earnings Call, May 02, 2013

Cell Therapeutics, Inc. will consider an amendment to the company’s amended and restated articles of incorporation to increase the total number of authorized shares from 150,333,333 to 215,333,333 and the total number of authorized shares of common stock from 150,000,000 to 215,000,000 at AGM to be held on June 26, 2013.